Robeauté raises €27.2M Seed round
14 January 2025· Paris, France· health, robotics, medical_devices, neurosurgery, ai, software_hardware, b2b
The funding will be used to advance Robeauté's microbot technology, initiate human trials in 2026, and establish operations in the US as the company pursues FDA approval, with plans for full go-to-market.
Investors
LeadPlural
Also participating
LocalGlobeCherry VenturesKindred VenturesThink.HealthAPEX VenturesBrainlab
About Robeauté
Stage
Seed
Headquarters
Paris, France
Founded
2017
Team Size
21–50
Sectors
healthroboticsmedical_devicesneurosurgeryaisoftware_hardwareb2b